FrontView REIT, Inc. Stock 12‑Month Price Target Cut to $22.29, Implies 34% Upside

FrontView REIT, Inc.'s average stock price target was reduced from $22.42 to $22.29 by 12 analysts, with a range of $19 to $24. This implies a 34% upside from the Sep. 30 closing price. The consensus rating remains 'Buy' with 9 Buys, 2 Holds, and 1 Sell.

Original reporting
Published Oct 1, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 7:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FrontView REIT, Inc. Stock 12‑Month Price Target Cut to $22.29, Implies 34% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target reduction may prompt short‑term price adjustments but the consensus rating remains a Buy, limiting downside.

02

Market read

Analyst price‑target cut is a modest negative catalyst for the stock, with limited broader market effect.

03

What to watch

Potential upside from upcoming mortgage‑backed securities pipeline not reflected in the target.

Relevance 7/10Novelty 5/10Timing: immediate

Background

FrontView REIT is a mortgage‑backed securities REIT focused on residential loan assets.

Market effects

Minor impact on the REIT sector as analysts adjust expectations for small‑cap mortgage REITs.

Limited to U.S. small‑cap REIT investors.

Low

Counterpoint

Some investors may view the modest target cut as an opportunity if they believe the underlying assets are undervalued.

Key entities

  • FrontView REIT, Inc.

    U.S. listed mortgage REIT (ticker FVRR).

Related articles

$FVRMed

FrontView REIT Q2 Earnings Call Highlights

FrontView REIT (NYSE:FVR) reported Q2 highlights including occupancy above 99% with two vacant properties. Management cited re-tenanting and redevelopment generating $1.6M in ABR and $29M estimated value. It acquired 17 properties for $58.2M at a 7.34% cap rate, and expects Q3 cap rates of 7.3% to 7.4%. Liquidity exceeded $200M; LTV 33%.

$FVRHigh

FrontView REIT Announces Second Quarter 2026 Results and Raises 2026 Net Investment and AFFO per Share Guidance

FrontView REIT, Inc. (FVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 For Immediate Release August 6, 2026 FrontView REIT Announces Second Quarter 2026 Results and Raises 2026 Net Investment and AFFO per Share Guidance Dallas, TX – FrontView REIT, Inc. (NYSE: FVR) (the “Company”, “FrontView”, “we”, “our”, or “us”), today announced its

$PSAMed

REIT ETF RDOG Rides M&A, Refinancing Wave to 22% Gain

RDOG, the ALPS REIT Dividend Dogs ETF, gained 22.1% year to date through July 17, helped by M&A, credit upgrades and refinancings in its holdings. National Storage Affiliates jumped 66.2% after Public Storage agreed to buy it in March. Other contributors included FrontView, Postal Realty and RLJ Lodging. Nareit reported 8 REIT mergers and privatizations worth $57.7B through June.

$SNPSMedAI 8/10

Synopsys signs $1bn-plus silicon IP deal with Amazon

Synopsys signed a multi-year, $1bn+ deal with Amazon for silicon IP solutions, making Amazon its lead customer. The agreement includes a license-plus-royalty model and collaboration on AI-driven chip design. Synopsys will also use Amazon's cloud services. Separately, Synopsys partnered with OpenAI to develop GPT-Synopsys for semiconductor design workflows.

$SYREMed

JPMorgan initiates Spyre stock with Overweight on IBD pipeline

JPMorgan initiated Spyre Therapeutics (NASDAQ:SYRE) with an Overweight rating and a $110 price target, citing its IBD pipeline and combination therapy potential. The stock has gained 441% in the past year. Other analysts have mixed views, with some downgrading due to valuation concerns and others maintaining Buy ratings. Spyre reported Phase II results for its rheumatoid arthritis program, which showed efficacy but did not meet internal thresholds for monotherapy prioritization.